Skip to main content
ScholarsBetaWeill Cornell Medicine

Overview

Dr. Pisapia is a board-certified anatomic pathologist and neuropathologist who specializes in the diagnosis of neoplasms and other disorders within the central nervous system.  He obtained his B.A. from Columbia University in 2000 and his M.D. from Weill Cornell Medical College in 2009.  He completed training in anatomic pathology at New York-Presbyterian Hospital - Weill Cornell Medical Center and his neuropathology fellowship training at New York-Presbyterian Hospital - Columbia University Medical Center.

Highlights

  1. 1
    Scientific reports · 2022
    BLBenjamin LiechtyMRMert Rory SabuncuDJDavid J Pisapia
    PMID: 36587030PMCID: PMC9805452DOISenior author25 citations
  2. 2
    Neuro-oncology advances · 2022
    MMMark M SouweidaneOEOlivier ElementoASAndrea SbonerJPJeffrey P. GreenfieldDJDavid J Pisapia
    PMID: 35475276PMCID: PMC9034114DOISenior author6 citations
  3. 3
    Acta neuropathologica communications · 2022
    BLBenjamin LiechtyJSJames SolomonDJDavid J Pisapia
    PMID: 36397144PMCID: PMC9670552DOISenior author6 citations

Publications

101 publications

Funding

7 grants

Active

2 grants
  • Co-I
    Quantitative susceptibility mapping for stroke risk prediction of vulnerable carotid plaques
    National Institute of Neurological Disorders and Stroke · 2022–2027
    R01NS123576-01A1
  • Co-I
    Development of novel preclinical models and therapeutics for ETMR
    Children's Cancer Research Fund · 2023–2026
    CCRF 226613-01
Completed grants (5)
  • Co-I
    Quantitative Susceptibility Mapping (QSM) as a Non-Invasive Imaging Biomarker for Predicting Neurodegeneration in Alzheimer's Disease
    National Institute on Aging · 2020–2025
    R21AG067466-01A1
  • Co-I
    Influence of pre-analytical factors in glioblastoma MGMT promoter methylation biomarker assay
    National Cancer Institute · 2024–2025 · via University of Washington, The
    No publications yet
    R01CA246503-05
  • Co-I
    State Selective Lethality: Exploiting a Previously Unrecognized Therapeutic Vulnerability in Glioblastoma
    William Rhodes Center for Glioblastoma - Collaborative Research Initiative · 2022–2023
    WRCG 223502-01
  • PI
    Machine Learning Approaches to Improve Histological Interpretation of Glioblastoma
    William Rhodes Center for Glioblastoma - Collaborative Research Initiative · 2020–2021
    WRCG 210432-01
  • Co-I
    Targeting Molecular Vulnerabilities of ATRX Mutant Gliomas
    William Rhodes Center for Glioblastoma - Collaborative Research Initiative · 2020–2021
    WRC 205030-01

Mentoring

1 menteeAll publications with mentees →